Background
Liebel-Flarsheim Company and Mallinckrodt Inc. owned patents covering certain methods and devices for use with powered fluid injectors — medical devices used to inject contrast media into patients during imaging procedures such as CT scans and MRIs. The critical commercial context: Medrad had developed a jacketless injector — one that did not use a pressure jacket around the syringe. This was a departure from the industry norm at the time.
During prosecution, Liebel-Flarsheim’s applicants had learned about Medrad’s jacketless injector and deliberately amended their claims to omit any requirement for a pressure jacket — specifically intending the claims to cover injectors without pressure jackets. Despite this clear prosecution history, the district court construed the claims to require pressure jackets because the specification described only embodiments using pressure jackets.
The district court granted summary judgment of non-infringement to Medrad on two grounds: (1) for the first two patents, it held the claims required pressure jackets around syringes; and (2) for other claims, it held the powered injector must directly use an electrical signal from a detector in a specific way. Since Medrad’s injectors used neither pressure jackets nor the required signal processing, the district court found no infringement. Liebel-Flarsheim appealed.
The Court’s Holding
The Federal Circuit reversed and remanded. Writing for the court, Judge Linn reiterated and reinforced a foundational principle of patent claim construction: courts may not read limitations from the specification into patent claims. Even when the specification describes only a single embodiment using a particular feature — here, pressure jackets — that does not restrict broader claim language to require that feature unless the claim itself expressly demands it or the patentee has clearly disavowed the broader scope.
The court emphasized that the prosecution history here cut decisively against importing the pressure-jacket limitation. The applicants had consciously and deliberately amended their claims to encompass jacketless injectors like Medrad’s. Construing the claims to nonetheless require pressure jackets would not only violate claim construction rules but would directly contradict the documented intent of the patent applicants during prosecution.
The Federal Circuit also reaffirmed that a patent describing only one embodiment does not automatically limit claims to that embodiment. Broader claim language covers more than the disclosed embodiments when there is no clear disclaimer or disavowal of the additional scope. The district court had improperly read the specification’s embodiment-specific details into the claims, shrinking claim scope well below what the language plainly covered.
Key Takeaways
- Courts may not import limitations from the specification into patent claims — the specification describes embodiments, but broader claim language controls scope unless the patentee clearly disclaims broader coverage.
- A patent describing only a single embodiment does not restrict broader claims to that embodiment in the absence of express claim language or clear disavowal.
- Prosecution history showing that applicants amended claims to broaden coverage (here, to include jacketless injectors) is strong evidence against reading the abandoned limitation back into the claims.
- Claim construction errors by district courts remain the most common basis for Federal Circuit reversal in patent cases.
- Medical device patentees should draft broad claim language and document in prosecution history their intent to cover designs beyond those specifically exemplified in the specification.
Why It Matters
Liebel-Flarsheim v. Medrad is a frequently cited authority for the principle that patent claims, not specifications, define the scope of protection. The temptation to limit claims to the described embodiments is perennial — district courts and litigants often focus on what the patent actually shows, forgetting that broader claim language may intentionally extend beyond any described example. The Federal Circuit’s reversal here reminds practitioners that a patent’s specification is a disclosure of how the invention can be made and used, not an outer boundary on what the claims cover.
For patent prosecutors and litigators, the lesson is clear: if a claim is written broadly enough to cover a competitor’s design, the specification’s silence about that design does not automatically shrink the claim. Conversely, defendants arguing non-infringement should not rely solely on pointing to what the specification describes — they must show the claim itself requires the limitation they seek to impose.